Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chytridiomycosis infection and heat compromises sperm quality in a threatened frog.

The Journal of experimental biology·2026
Same author

Protocolized Pain Assessment and Management in Pediatric Trauma Patients.

The Journal of surgical research·2026
Same author

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Clinical genitourinary cancer·2026
Same author

International Delphi consensus on single-port robotic radical prostatectomy: patient selection, surgical technique, and training.

BJU international·2026
Same author

Inflammation induced by snake venoms optimizes envenomation.

The Journal of physiology·2026
Same author

Integrated Cardio-oncology Service.

Cardiac failure review·2026

Related Experiment Video

Updated: Aug 13, 2025

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

13.0K

ProNGF Expression and Targeting in Glioblastoma Multiforme.

Mark Marsland1,2, Amiee Dowdell1,2, Sam Faulkner1,2

  • 1School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia.

International Journal of Molecular Sciences
|January 21, 2023
PubMed
Summary

Pro-nerve growth factor (proNGF) is elevated in glioblastoma multiforme (GBM), a deadly brain cancer. Targeting proNGF shows potential for inhibiting GBM cell growth, but does not enhance standard chemotherapy efficacy.

Keywords:
biomarkerglioblastoma multiformeproNGFtherapeutic target

More Related Videos

Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

2.9K
Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
04:01

Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures

Published on: June 23, 2023

1.8K

Related Experiment Videos

Last Updated: Aug 13, 2025

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

13.0K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

2.9K
Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
04:01

Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures

Published on: June 23, 2023

1.8K

Area of Science:

  • Neuro-oncology
  • Cancer biology
  • Molecular pathology

Background:

  • Glioblastoma multiforme (GBM) is an aggressive brain cancer with limited treatment options.
  • Temozolomide (TMZ) is the standard chemotherapy, but its efficacy is often restricted.
  • Nerve growth factor (NGF) and its precursor proNGF are implicated in tumor progression, with proNGF's role in GBM being previously uninvestigated.

Purpose of the Study:

  • To investigate the expression and biological activity of proNGF in GBM.
  • To determine if proNGF can serve as a biomarker or therapeutic target for GBM.

Main Methods:

  • Immunohistochemistry and digital quantification of proNGF in GBM and low-grade glioma patient tissues (n=72 and n=20, respectively).
  • Western blotting to detect proNGF in GBM cell lines.
  • In vitro studies using anti-proNGF blocking antibodies on GBM cells.
  • In vivo studies using subcutaneous xenografts of human GBM cells treated with anti-proNGF antibodies and TMZ.

Main Results:

  • ProNGF expression was significantly higher in GBM compared to low-grade gliomas.
  • ProNGF was detected in GBM patient plasma and cell lines.
  • Anti-proNGF antibodies inhibited GBM cell growth, particularly in cells with methylated MGMT promoter.
  • Targeting proNGF did not improve TMZ efficacy in vitro or in vivo; antibodies only slightly reduced tumor volume.

Conclusions:

  • ProNGF is overexpressed in GBM and contributes to cancer cell growth.
  • ProNGF represents a potential biomarker and therapeutic target for GBM.
  • Further research is needed to fully elucidate the clinical utility of targeting proNGF in GBM treatment strategies.